CTC Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

CTC Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$662K	Buy	+2,100	New	+$630K	1.38%	28

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CTC Capital Management's VRTX Position: Q1 2023 in Review

CTC Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2023: 2,100 shares worth $662K. The stake represents 1.38% of the portfolio and ranks #28 among its holdings.

1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

CTC Capital Management held 2,100 shares of Vertex Pharmaceuticals worth $662K as of Q1 2023.
Vertex Pharmaceuticals was a new CTC Capital Management position in Q1 2023.
Vertex Pharmaceuticals made up 1.38% of CTC Capital Management's portfolio in Q1 2023, its #28 holding.
1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on CTC Capital Management's 13F filing for Q1 2023, filed 5 May 2023.